|
24 Mar 2026
|
Sai Parenterals
|
Hem Securities
|
475.00
|
|
|
|
IPO Subscribe
|
|
|
Company is a diversified pharmaceutical formulations company with capabilities in research, development and manufacturing. Company is in the business of (i) Branded Generic Formulations and (ii) Contract Development and Manufacturing Organisation (CDMO) products and services for the domestic and international markets. Company's portfolio includes formulation products across various therapeutic areas like cardiovascular, neuropsychiatry, anti-diabetic, respiratory health, antibiotics,...
|
|
23 Mar 2026
|
Sai Parenterals
|
Deven Choksey
|
475.00
|
|
|
|
IPO Note
|
|
|
The company's historical financials and overall business model offer limited predictive value as the company is at an inflection point, transitioning into an export-oriented entity.
|
|
23 Mar 2026
|
Sai Parenterals
|
Ventura
|
475.00
|
|
|
|
IPO Subscribe
|
|
|
|
|
20 Mar 2026
|
Sai Parenterals
|
SBI Securities
|
475.00
|
|
|
|
IPO Subscribe
|
|
|
Sai Parenteral's Ltd. (SPL) is a diversified pharmaceutical formulations company, engaged in the business of (a) Branded Generic Formulations, and (b) Contract Development and Manufacturing Organisation (CDMO) products & services for the domestic and international markets. The company's portfolio includes formulation products, covering both high-value and high-volume categories across therapeutic areas like cardiovascular, neuropsychiatry, anti-diabetic, etc., with offerings across...
|
|
20 Mar 2026
|
Sai Parenterals
|
ICICI Direct
|
475.00
|
|
|
|
IPO Note
|
|
|
About the Company: Sai Parenteral's is a Hyderabad-based global formulations company engaged in developing and manufacturing of formulations across multiple therapeutic areas and dosage forms. The company owns installed capacities for injectables, tablets, capsules, liquid orals and ointments, with a total of 5 manufacturing facilities in...
|